Cargando…

The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib

BACKGROUND AND AIMS: The present study aims to investigate the role of the prognostic nutritional index (PNI) on survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. METHODS: This multicentric study included a training cohort of 194 HCC patients and three externa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caputo, Francesco, Dadduzio, Vincenzo, Tovoli, Francesco, Bertolini, Giulia, Cabibbo, Giuseppe, Cerma, Krisida, Vivaldi, Caterina, Faloppi, Luca, Rizzato, Mario Domenico, Piscaglia, Fabio, Celsa, Ciro, Fornaro, Lorenzo, Marisi, Giorgia, Conti, Fabio, Silvestris, Nicola, Silletta, Marianna, Lonardi, Sara, Granito, Alessandro, Stornello, Caterina, Massa, Valentina, Astara, Giorgio, Delcuratolo, Sabina, Cascinu, Stefano, Scartozzi, Mario, Casadei-Gardini, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205300/ https://www.ncbi.nlm.nih.gov/pubmed/32379785 http://dx.doi.org/10.1371/journal.pone.0232449

Ejemplares similares

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights
por: Caputo, Francesco, et al.
Publicado: (2019)

Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC
por: Granito, Alessandro, et al.
Publicado: (2021)

COVID-19: Has the Liver Been Spared?
por: Brandi, Nicolò, et al.
Publicado: (2023)

Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials
por: Casadei Gardini, Andrea, et al.
Publicado: (2019)

Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
por: Casadei Gardini, Andrea, et al.
Publicado: (2017)

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
por: Marisi, Giorgia, et al.
Publicado: (2019)

Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5)
por: Terzi, Eleonora, et al.
Publicado: (2022)

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
por: Burgio, Valentina, et al.
Publicado: (2021)

Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New
por: Faloppi, Luca, et al.
Publicado: (2016)

Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology
por: Aprile, Giuseppe, et al.
Publicado: (2015)

Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib
por: Sansone, Vito, et al.
Publicado: (2021)

Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trials
por: Tovoli, Francesco, et al.
Publicado: (2021)

Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease
por: Ferri, Silvia, et al.
Publicado: (2022)

Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy
por: Casadei-Gardini, Andrea, et al.
Publicado: (2023)

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report
por: Casadei Gardini, Andrea, et al.
Publicado: (2016)

Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer
por: Giampieri, Riccardo, et al.
Publicado: (2015)

Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders
por: Ielasi, Luca, et al.
Publicado: (2021)

Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma
por: Ielasi, Luca, et al.
Publicado: (2023)

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
por: Marisi, Giorgia, et al.
Publicado: (2018)

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin
por: De Matteis, Serena, et al.
Publicado: (2019)

Lung Ultrasound Is Often, but Not Always, Normal in Healthy Subjects: Considerations for COVID-19 Pandemic
por: Raiteri, Alberto, et al.
Publicado: (2021)

Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis
por: Bittoni, Alessandro, et al.
Publicado: (2015)

Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis
por: Garajová, Ingrid, et al.
Publicado: (2023)

Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review
por: Gardini, Andrea Casadei, et al.
Publicado: (2017)

Validation of the pathological narcissistic inventory (PNI) and its brief form (B-PNI) in the Arabic language
por: Malaeb, Diana, et al.
Publicado: (2023)

The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment
por: D’Anzeo, Marco, et al.
Publicado: (2014)

TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience
por: Rimini, Margherita, et al.
Publicado: (2023)

Autoantibodies to speckled protein family in primary biliary cholangitis
por: Granito, Alessandro, et al.
Publicado: (2021)

Anti-ganglioside antibodies and celiac disease
por: Granito, Alessandro, et al.
Publicado: (2021)

Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment
por: Personeni, Nicola, et al.
Publicado: (2022)

Cancer Stem Cell Gene Profile as Predictor of Relapse in High Risk Stage II and Stage III, Radically Resected Colon Cancer Patients
por: Giampieri, Riccardo, et al.
Publicado: (2013)

The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy
por: Faloppi, Luca, et al.
Publicado: (2016)

Perineural Invasion (PNI) Definition, Histopathological Parameters of PNI in Oral Squamous Cell Carcinoma With Molecular Insight and Prognostic Significance
por: Goswami, Parth R, et al.
Publicado: (2023)

Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma
por: Rapposelli, I.G., et al.
Publicado: (2021)

Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice
por: Lai, Eleonora, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p0ah3dv8ru7i0ms7hn5d304pm7